Showing results (361-370 of 415) with videos related to

Sort By:
Pageof 42
Blood|February 4, 2010
High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host diseaseLeo Luznik, Javier Bolaños-Meade, Marianna Zahurak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2022
Project Confirm: Accelerated Drug Approvals for Chronic Myeloid LeukemiaKendra L Sweet, Jorge E Cortes, Jane F Apperley, et al.
Leukemia|June 24, 2020
Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND studyAndreas Hochhaus, Carlo Gambacorti-Passerini, Camille Abboud, et al.
Blood|February 27, 2016
4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cellsSeongseok Yun, Nicole D Vincelette, Katherine L B Knorr, et al.
Leukemia Research|September 5, 2017
Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literatureKelly J Norsworthy, Amy E DeZern, Hua-Ling Tsai, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 2, 2019
Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant CyclophosphamideShannon R McCurdy, Christopher G Kanakry, Hua-Ling Tsai, et al.
Cancer Research|June 17, 2006
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasmsSteven D Gore, Stephen Baylin, Elizabeth Sugar, et al.
Blood Advances|August 20, 2020
Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adultsHeather J Symons, Marianna Zahurak, Yilin Cao, et al.
Pageof 42